Triptorelin Market Size & Share, by Drug Type (Pamoate, Acetate, Embonate), Application (Prostate Cancer, Radical Prostatectomy, Endometriosis, Salivary Gland Cancer, Central Precocious Puberty), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

  • Report ID: 5019
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2025-2037

Triptorelin Market size was over USD 11.1 billion in 2024 and is poised to exceed USD 21.99 billion by 2037, witnessing over 5.4% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of triptorelin is evaluated at USD 12.08 billion.

The growing prevalence of central precocious puberty among children below the age of 8 or 9 is poised to dominate the market demand for triptorelin. Moreover, its frequency has been boosted since covid19 owing to growing stress among children. Hence, the use of triptorelin increased and is anticipated to boost even further owing to this factor. Triptorelin injection (Triptodur) for the treatment of central precocious puberty (CPP), a condition that causes puberty in children at an early stage and leads to faster bone growth and sexual traits development, in children aged 2 and older.

Inconsistency between biological sex and self-identified gender is a problem for transgender people. Hence, the use of triptorelin is also growing among transgender people for hormone replacement therapy. Hormone therapy is a common transitional treatment for transgender men and women. To promote virilization and decrease feminizing traits in transgender men, exogenous testosterone is administered. Anti-androgens are used as adjuncts to help suppress masculinizing characteristics in transgender women, and exogenous estrogen is used to help feminize patients. Moreover, triptorelin has the function of enabling control over ovarian function during ovarian stimulation cycles. It suppresses the LH peak that triggers ovulation, preventing spontaneous ovulation as a result. Additionally, it permits tracking of ovarian activity in people who have frozen embryo transfers or egg donation cycles and have an ovarian function. As a result, the endometrium could be in the best possible shape for embryo implantation.


Get more information on this report: Request Free Sample PDF

Triptorelin Market: Growth Drivers and Challenges

Growth Drivers

  • Growing Prevalence of HIV

According to the World Health Organization, about 38.4 million people worldwide were living with HIV in 2021. Hence, there has been going numerous trials to check the efficiency of triptorelin in HIV patient. However, even though this treatment is not widely used in HIV patients, owing to the ongoing research & development and huge investment from the pharmaceutical organization for the same, triptorelin treatment is estimated to be used to treat such patients during the forecast timeframe.

  • Rise in Prostate Cancer Among Men

The second most frequently diagnosed cancer and the fifth highest cause of cancer death in males globally is considered to be prostate cancer, with a poised 1,414,000 new cancer cases and 375,304 deaths in 2020. The hormone testosterone is required for prostate cancer to develop. The testicles in men produce almost all of the testosterone. Triptorelin inhibits testosterone production in the testicles, lowering testosterone levels and slowing or halting the proliferation of cancer cells.

  • Surge in the Number of Women Suffering from Endometriosis

According to the World Health Organization, globally about 10% or 190 million women or girls of reproductive age are affected by endometriosis. It causes life-impacting pain in women during sexual intercourse, periods, bowel moment, and more. Hence, its treatment is necessary. Therefore, the use of triptorelin is growing since it has been proven effective with an acceptable safety profile. Also, since it has positive results on the reproductive part of the women, the problem in becoming could be diagnosed.

Challenges

  • High Price of Triptorelin Drugs - Despite having a huge client base, the triptorelin market has a significant obstacle which includes expensive triptorelin drug manufacturing costs, which are passed down to consumers as high medical costs. The expense of manufacturing a drug is further boosted by the fact that the raw materials are unique to the drug, making it essential that they be of high quality. Additionally, the product availability is hindered to those who could afford it owing to the intricacy of the triptorelin manufacturing process, which involves a variety of biological or chemical procedures.
  • Side Effects of Triptorelin
  • Lack of Awareness Among People

Triptorelin Market: Key Insights

Base Year

2024

Forecast Year

2025-2037

CAGR

5.4%

Base Year Market Size (2024)

USD 11.1 billion

Forecast Year Market Size (2037)

USD 21.99 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Get more information on this report: Request Free Sample PDF

Triptorelin Segmentation

Drug Type (Triptorelin Pamoate, Triptorelin Acetate, Triptorelin Embonate)

Triptorelin market from the triptorelin embonate segment is expected to generate the highest revenue by the end of 2037. The growth of the segment can be attributed to the growing prevalence of prostate cancer since it is highly used in treating it. However, this is also used in treating endometriosis, and uterine fibroids. This is because, triptorelin embonate functions by restricting the release of hormones known as gonadotropins, which stimulate the testicles or ovaries.

Distribution Channel (Online Pharmacy, Hospital Pharmacy, others)

The hospital pharmacy segment in the triptorelin market is poised to have noteworthy growth over the forecast period. This segment expansion is expected to be influenced by rising hospital admission for gynecological disorders, or cancer. Also, these drugs are usually prescribed by a medical professional in the hospital, hence the attached pharmacies to the hospital make it convenient for the patient to find their prescribed drugs.

Our in-depth analysis of the global market includes the following segments:

 

         Drug Type

  • Triptorelin Pamoate
  • Triptorelin Acetate
  • Triptorelin Embonate

         Application

  • Prostate Cancer
  • Radical Prostatectomy
  • Endometriosis
  • Salivary Gland Cancer
  • Central Precocious Puberty

        Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Triptorelin Industry- Regional Synopsis

North American Market Forecast

North America industry is predicted to dominate majority revenue share by 2037, backed by growing demand for hormone therapy among men. Also, the number of transgender men in this region is also high, and are also demanding hormone therapy. About 2 million adults and youth identified themselves as transgender in the US in 2022.

APAC Market Statistics

The Asia Pacific triptorelin market is poised to have a significant growth over the forecast period. There has been growing awareness among people in this region regarding various treatments available in the market. This is why, the triptorelin market demand for triptorelin is set to grow in this region. Moreover, Asia Pacific the gaining popularity in medical treatment. Hong Kong, Singapore, South Korea, Japan, India and there are few which are considered to be the medical hub.

Research Nester
Get more information on this report: Request Free Sample PDF

Top Featured Companies Dominating the Triptorelin Market

    • Ipsen Pharma
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Bachem
    • Chengdu Tiantaishan pharmaceutical
    • Ferring Pharmaceuticals
    • Tecnofarma SA
    • Dr. Reddy's Laboratories Ltd
    • Arbor Pharmaceutical, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Debiopharm International SA
    • Verity Pharmaceuticals Inc.

In the News

  • To speed up innovation in women's health, Ferring Pharmaceuticals and BioInnovation announce a new strategic partnership. The goal of the expanded partnership between the BioInnovation Institute Foundation (BII) and Ferring Pharmaceuticals A/S (Ferring) is to accelerate top-tier life science innovation in the field of women's health.
  • Treprostinil Injection, a therapeutically similar generic form of Remodulin (treprostinil) Injection, was made available on the U.S. market by Dr. Reddy's Laboratories Ltd.

Author Credits:  Radhika Pawar


  • Report ID: 5019
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of triptorelin is evaluated at USD 12.08 billion.

The triptorelin market size was over USD 11.1 billion in 2024 and is poised to exceed USD 21.99 billion by 2037, witnessing over 5.4% CAGR during the forecast period i.e., between 2025-2037. The market growth is driven by growing prevalence of HIV, the rise in prostate cancer among people, and the surge in the number of women suffering from endometriosis.

North America industry is predicted to dominate majority revenue share by 2037, backed by growing demand for hormone therapy among men.

The major players in the market are Ipsen Pharma, Bachem, Chengdu Tiantaishan pharmaceutical, Ferring Pharmaceuticals, Tecnofarma SA, Dr. Reddy's Laboratories Ltd, Arbor Pharmaceutical, Inc., Teva Pharmaceutical Industries Ltd., Debiopharm International SA, Verity Pharmaceuticals Inc.
Triptorelin Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample